Clinical Trial Training
7-10 November 2017 in Bobo Dioulasso, Burkina Fasso
Click here for more information

Vaccines R&D 2017
13-15 November 2017 in Washington, DC, US

66th Annual Meeting of American Society of Tropical Medecine & Hygiene
5-9 November 2017 in Baltimore, Maryland, US

Scientific Colloquium on Heterologous Prime Boost Vaccination
29 September 2017 in Leuven, Belgium

3rd African Conference on Emerging Infectious Diseases and Biosecurity
16-18 August 2017 in Accra, Ghana

9th IAS Conference on HIV Science
23-26 July 2017 in Paris, France

International Summer School ISPED
Statistical analysis of big data in systems immunology
3-7 July 2017 in Bordeaux, France
More information :

3rd West African Sub-Regional Conference
“Post Ebola Health Challenges in West Africa”
11-13 May 2017 in Conakry, Guinea

2nd Joint EBOVAC1 & EBOVAC2 annual meeting

The second joint EBOVAC1 & EBOVAC2 annual meeting was held in Windsor on 14-16 November 2016. Over 100 participants from both consortia attended. It was the opportunity to share information on the progress and results of 2016 activities.

1st Joint EBOVAC1 & EBOVAC2 annual meeting

The first EBOVAC1 & EBOVAC2 annual meetings was held in Paris from 20th to 22th of January 2016 at Novotel Convention & Wellness, Roissy.

EBOVAC2 Kick-off meeting

The project kick-off meeting was held at the Biopark auditorium, Paris on the 12th of February 2015.

More than 50 participants attended with representatives from the whole consortium, IMI2 and invited participants.

Targeting Ebola

EBOVAC1 and EBOVAC2 presented a poster entitled “Development of a prophylactic Ebola Vaccine using and heterologous prime-boost regimen” at Targeting Ebola, Paris, 28-29 May 2015.

To view the poster, please click here

EBOVAC2 coordinator, Rodolphe Thiebaut, made a presentation concerning accelerated development of Ebola vaccines. After explaining the context and the challenges, he presented the current development pipeline of vaccine trials and the limitations of existing methodogies. He concluded by outlining perspectives for the future of Ebola vaccine development.


Rodolphe Thiébaut, Ebovac2 coordinator © Ebovac2


  • 17 January 2018

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018

  • 02 January 2018

    The 4th edition of our EBOVAC2 newlsetter was released on the 21st of December 2017.

  • 27 October 2017

    The 3rd EBOVAC2 Newsletter is now available here. Our October 2017 issue includes an interview with Dr Houreratou Barry, PI of the Centre Muraz site.

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 27 June 2017

    The 2nd EBOVAC2 newsletter June 2017 is now available here!

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research